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Abstract
Sagopilone, an optimized fully synthetic epothilone, is a microtubule-stabilizing compound that has shown high in vitro and
in vivo activity against a broad range of human tumor models. We analyzed the differential mechanism of action of
sagopilone in non-small cell lung cancer cell lines in vitro. Sagopilone inhibited proliferation of non-small cell lung cancer
cell lines at lower nanomolar concentration. The treatment with sagopilone caused strong disturbances of cellular
cytoskeletal organization. Two concentration-dependent phenotypes were observed. At 2.5 nM sagopilone or 4 nM
paclitaxel an aneuploid phenotype occur whereas a mitotic arrest phenotype was induced by 40 nM sagopilone or
paclitaxel. Interestingly, treatment with 2.5 nM of sagopilone effectively inhibited cell proliferation, but - compared to high
concentrations (40 nM) - only marginally induced apoptosis. Treatment with a high versus a low concentration of
sagopilone or paclitaxel regulates a non-overlapping set of genes, indicating that both phenotypes substantially differ from
each other. Genes involved in G2/M phase transition and the spindle assembly checkpoint, like Cyclin B1 and BUBR1 were
upregulated by treatment with 40 nM sagopilone. Unexpectedly, also genes involved in DNA damage response were
upregulated under that treatment. In contrast, treatment of A549 cells with a low concentration of sagopilone revealed an
upregulation of direct transcriptional target genes of TP53, like CDKN1A, MDM2, GADD45A, FAS. Knockdown of TP53, which
inhibited the transcriptional induction of TP53 target genes, led to a significant increase in apoptosis induction in A549 cells
when treated with a low concentration of sagopilone. The results indicate that activation of TP53 and its downstream
effectors like CDKN1A by low concentrations of sagopilone is responsible for the relative apoptosis resistance of A549 cells
and might represent a mechanism of resistance to sagopilone.
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Introduction
Lung cancer is one of the leading causes of cancer death
worldwide, as it is often only diagnosed at advanced stages and
displays a high degree of resistance to the chemotherapeutic
regimens used. [1–5]. Sagopilone (SAG) is a fully synthetic
epothilone, currently in clinical development that was optimized to
overcome limitations frequently associated with taxanes, conven-
tional tubulin-binding agents (TBAs) as for example MDR
mediated resistant mechanisms [6]. SAG has demonstrated high
in vitro and in vivo activity in a range of tumor models compared
with paclitaxel (PAC) and other commonly used chemotherapeutic
agents [6]. With strong anti-tumor activity been observed in
NSCLC (non-small cell lung cancer) cell lines in vitro and primary
human NSCLC mouse xenograft models, SAG may provide a
potential new treatment opportunity for NSCLC [7].
Several studies describe predictive markers of response for
NSCLC cell lines, as expression of the excision repair cross-
complementation group 1 (ERCC1) gene for platinum compounds
[8] or the epidermal growth factor receptor (EGFR) mutational
status for the EGFR tyrosine-kinase inhibitors (gefitinib and
erlotinib) [9]; [10]. With regard to resistance to TBAs, reports on
cell lines selected for PAC resistance through long-term culture in
the presence of the drug showed increased levels of TUBB3 (beta
III tubulin) protein expression [11]. In contrast, their patupilone
(epothilone B) resistant counterpart, incubated in the same
manner, showed low TUBB3 protein expression [11]. These data
suggest that TUBB3 contributes to the cellular resistance towards
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other markers that can predict SAG response.
Mutations in tumor-suppressor genes, which plays a central role
in cellular response to DNA damage, cell cycle regulation, and
apoptosis [12], were found in about 50% of all NSCLC cases [13].
However, the role of TP53 in response to TBAs like PAC has been
contested: Some groups reported no correlation between TP53
mutational status and sensitivity to PAC [14]; [15], while others
observed that lack of TP53 activity resulted in increased
chemosensitivity to PAC [16]; [17]. These findings suggest that
the TP53 mutational status and altered TP53 activity might
influence the sensitivity of cells to SAG. To address this question,
we have analyzed the influence of TP53 on the ability of SAG to
induce apoptosis in an NSCLC model in vitro.
The identification of stratification biomakers or drug- or drug
target-related response markers might considerably improve the
outcome of the therapy and would lead to a shift towards more
tailored therapies against specific disease types [18]. The optimal
treatment for patients suffering from NSCLC will increasingly rely
on biomarker analysis to identify the patient population who will
benefit most from a certain mono- or combination therapy.
Nevertheless, biomarker identification and validation remains a
major challenge [19] and it is therefore important to accompany
the development of new therapeutic agents for patients with
NSCLC with research on patient stratification and the identifica-
tion and validation of clinical biomarkers which predict response.
As part of this process, it is vital to understand how the activity of
promising new agents is influenced by alterations in key cellular
pathways, and vice versa.
The aim of our translational program was to examine the
activity of SAG in vitro in a panel of NSCLC cell lines, to further
analyze its mechanism of action and to compare it with the effects
of PAC and to investigate possible resistance mechanisms as well
as predictors of response based on gene expression profiling.
Materials and Methods
Cells and compounds
Human lung carcinoma cell lines (A549, NCI-H1437, NCI-
H23, NCI-H522, NCI-H226, NCI-H460) were obtained from the
American Type Culture Collection (ATCC) and cultured
according to recommended protocols. SAG was synthesized at
Bayer Healthcare Laboratories through total syntheses. PAC was
purchased from Sigma-Aldrich (Munich, Germany). The pan-
caspase inhibitor ZVAD.fmk was purchased from Bachem,
(Heidelberg, Germany). All media and supplements for cell culture
were purchased from Biochrom AG (Berlin, Germany). Stock
solutions were prepared as previously described [20]. For selection
of stably transduced cell lines Hygromycin was purchased from
Roche (Mannheim, Germany).
Tumor cell proliferation assay
The effect of SAG or PAC on the proliferation of lung cancer
was assessed using a cell proliferation assay based on staining cells
with crystal violet as described before [20]. IC50 values were
calculated from three independent experiments using the Sigma-
plot software (SPSS, Friedrichsdorf, Germany).
In vitro analysis of effects on the cytoskeleton, the cell
cycle and apoptosis
A549 cells were incubated with vehicle (ethanol 0.1%), 2.5 nM
or 40 nM SAG for 20 h, fixed with 4% paraformaldehyde and
stained with a monoclonal mouse anti-a-tubulin antibody (1:1000)
(Sigma-Aldrich), Alexa FluorH 488-linked goat anti-mouse IgG
secondary antibody (1:250) (Invitrogen Inc., Carlsbad, CA, USA)
and DRAQ5 (Biostatus, Leicestershire, UK), according to
standard protocols. Fixed and stained cells were analyzed using
a Zeiss LSM 510 META microscope (Carl Zeiss AG, Jena,
Germany) equipped with a Plan-ApochromatH 63x/1.4 (oil DIC)
objective. Zeiss LSM software (version 3.0 SP3) was employed for
confocal imaging.
Fluorescence-activated cell sorter (FACS) analysis was per-
formed to determine cell cycle distribution of SAG- or PAC-
treated cells. Cells were incubated with SAG at the indicated
concentrations or vehicle for 18 h, fixed with 70% ethanol, and
stained with 50 mg/mL propidium iodide (PI) (Sigma-Aldrich).
Cellular DNA content was determined by flow cytometry using the
BD FACSCalibur
TM (Becton, Dickinson and Company, San Jose,
CA, USA) and data were analyzed with the CellQuest
TM software
(Becton, Dickinson and Company). To investigate apoptosis by
FACS, A549 cells were incubated continuously for 72 hrs with the
indicated concentrations of SAG or vehicle, trypsinized and
stained with DiOC6(3) (3,39-dihexyloxacarbocyanine iodide) (In-
vitrogen Inc.) and PI as described before [21].
Quantitative Real-Time PCR and Western Blot
RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden,
Germany), cDNA was generated using SuperScript First Strand
Synthesis System (Invitrogen Inc.). Real-time PCR was performed
with gene expression assays from Applied Biosystems: p21 (#Hs
00355782_m1), TP53 (#Hs00153340_m1), Cyclin B1 (#Hs00
259126_m1), BUBR1 (Hs00176169_m1), FAS (Hs00163653_m1),
GADD45A (Hs00169255_m1), MDM2 (Hs00242813_m1), and
HPRT (#4326321E) as endogenous control. Reactions were set up
in triplicates using the TaqMan FAST Universal PCR Mastermix
and recorded in a 7500 Fast Real-Time PCR-System (Applied
Biosystems). The relative expression of each gene was quantified
according to the comparative threshold cycle method (DD Ct
method) with equal amplification efficiencies of the target and the
endogenous control.
Proteins were extracted using M-PER Mammalian Protein
Extraction Reagent (Pierce, Perbio Science, Bonn, Germany). The
protein concentrations of the lysates were determined with the
BCA Protein Assay Kit (Pierce) according to the manufacturer’s
instructions. Equal amounts of proteins were separated on a 4–
12% Bis-Tris gel (Invitrogen) in an XCell SureLock electropho-
resis chamber (Invitrogen) filled with MOPS SDS running buffer
and transferred to a PVDF membrane (Invitrogen) according to
the manufacturer’s instructions. After blocking of unspecific
binding sites, the membrane was probed with antibodies specific
for CDKN1A (abcam, #16767), TP53 (BD Pharmingen,
#15801A), BUB1B (BD Transduction Laboratories, # 612502),
Cyclin B1 (BD Pharmingen, # 554176), cH2AX (upstate, # 05-
636), PARP (BD Pharmingen, # 551024), phospho-Ser/Thr-
MPM-2 (upstate # 05-368), and GAPDH (Advanced Immuno-
Chemical, # RGM2/Clone 6C5) as loading control.
RNA extraction for gene expression analysis
A549 cells were seeded in 10 cm cell culture plates and allowed
to attach overnight. The cells were then treated with medium
containing either 2.5 nM SAG, 40 nM SAG, 4 nM PAC or
40 nM PAC, respectively, vehicle (ethanol 0.1%), or were left
untreated for 18 hours. Total RNA was extracted using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) including a DNase I
(Qiagen) step to eliminate genomic DNA. Total RNA was checked
for integrity using the RNA LabChips on the Agilent Bioanalyzer
2100 (Agilent Technologies Inc., Palo Alto, CA, USA) and the
concentration was determined on a Nanodrop spectrophotometer
Molecular Mode of Action of Sagopilone in NSCLC
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integrity numbers [22] larger than 9.5.
Affymetrix GeneChipH analysis
The One-Cycle Eukaryotic Target Labeling Kit (Affymetrix
Inc., Santa Clara, CA, USA) was used according to the
manufacturer’s instructions. Briefly, 2 mg of high quality total
RNA was reverse-transcribed using a T7 tagged oligo-dT primer
for the first-strand cDNA synthesis reaction. After RNase H-
mediated second-strand cDNA synthesis, the double-stranded
cDNA was purified and served as template for the subsequent in
vitro transcription reaction which generates biotin-labeled comple-
mentary RNA (cRNA). The biotinylated cRNA was then cleaned
up, fragmented and hybridized to GeneChip HGU133Plus2.0
expression arrays (Affymetrix, Inc., Santa Clara, CA, USA.),
which contain 54675 probe sets. The GeneChips were washed and
stained with streptavidin-phycoerythrin on a GeneChip Fluidics
Station 450 (Affymetrix). After washing, the arrays were scanned
on an Affymetrix GeneChip 3000 scanner with autoloader. A total
of 30 HGU133Plus2.0 arrays were processed with n=5 biological
replicates for all treatment groups.
Expression analyses were performed with the Expressionist Pro
4.0 software (Genedata AG, Basel, Switzerland). The quality of the
data files (CEL format) containing probe level expression data was
checked and refined using the Expressionist Refiner software
(Genedata AG). The refiner process was performed by clustering
of samples on feature intensity level. This allows the identification
of possible outliers on feature intensity level. Subsequently, refined
CEL files were condensed with MAS5.0 algorithm (Affymetrix)
and LOWESS normalized using all experiments as a reference.
The normalized expression data sets were loaded into the CoBi
database (Genedata) and analyzed with the Genedata Expression-
ist software. Principle Component Analysis (PCA) and hierarchical
clustering was performed with the Expressionist Analyst Pro 4.0
software (Genedata). A valid value proportion analysis was
performed for each group (4 of 5 probe sets had to show a signal)
and the resultant groups of probe sets were united. These data
were subjected to a number of pairwise comparisons using the
Expressionist Analyst Pro 4.0 software (Genedata). Statistical
analyses included pairwise comparisons between SAG- or PAC
treated samples and vehicle-treated samples. Probe sets were
considered to be regulated if they were outside of the ellipsoid
region in the Volcano plot applying the following thresholds:
Volcano plot: .5x-fold change and P-value ,1610-5 from T-test
for 40 nM SAG and PAC; for 2.5 nM SAG and 4 nM PAC .3-
fold change and P-value ,5610-3. Venn intersection analyses of
significantly regulated genes were performed to identify genes
regulated commonly by different treatments using the Expression-
ist Analyst Pro 4.0 software. Pathway analyses were performed
with the GeneGo Metacore (St. Joseph, MI, USA) database and
software tools. All Affymetrix cel-file data are available via the
ArrayExpress accession number E-MTAB-377.
Cloning of shRNA constructs
The BLOCK-iT RNAi Designer algorithm (Invitrogen, Carls-
bad, CA, USA) was used to analyze TP53 mRNA (GenBank
accession number, NM_000546.4) and to identify three target
sequences for shRNA, i.e. shTP53_1 (sense) 59-GCATCTTATCC-
GAGTGGAAGG-39and59-CCTTCCACTCGGATAAGATGC-
39; shTP53_2 (sense) 59-GACTCCAGTGGTAATCTAC-39 and
59-GTAGATTACCACTGGAGTC-39; shTP53_3 (sense) 59-GC-
GCACAGAGGAAGAGAATCT-39 and 59-AGATTCTCTTC-
CTCTGTGCGC-39. The target sequences for a non-specific
control shRNA (non-targeting shRNA) were shCtrl1 (sense)
59-TAAGGCTATGAAGAGATAC-39 and 59-GTATCTCTTC-
ATAGCCTTA-39 and shCtrl2 (sense) 59-TTCTCCGAACGT-
GTCACGT-39 and 59-ACGTGACACGTTCGGAGAA-39.
Complementary synthetic DNA oligonucleotides were hybridized
and inserted into pENTR/U6 vector (Invitrogen). shRNA cassettes
were recombined by Gateway cloning into a modified pLenti-6
destination vector (pGT3, Invitrogen) to generate lentiviral shRNA
expression constructs shCtrl1, shCtrl2, shTP53_1, shTP53_2, and
shTP53_3. All constructs were confirmed by DNA sequencing at the
Services in Molecular Biology (SMB), Berlin, Germany.
Production of lentivirus and transduction of A549 cells
293FT cells were transfected with different pGT3 expression
vectors containing TP53 shRNAs or nontarget control shRNA.
Lentivirus production was carried out according to the BLOCK-
iT U6 RNAi Entry Vector Kit User Manual (Invitrogen). A549
cells were infected with lentiviruses recombinant for shTP53_1,
shTP53_2, shTP53_3, or non-target control shRNAs shCtrl1 and
shCtrl2, respectively, and selected with hygromycin (100 mg/ml).
Individual clones were expanded and tested for TP53- knockdown
efficiency by qRT-PCR (data not shown) and immunoblotting.
Results
Sagopilone efficaciously inhibits proliferation of NSCLC
cell lines in the nanomolar range
The anti-proliferative activity of SAG and PAC was examined
in 6 non-small cell lung cancer cell lines of different subtypes
(adenocarcinoma: A549, NCI-H1437, NCI-H23, NCI-H522;
squamous cell carcinoma: NCI-H226; large cell lung carcinoma:
NCI-H460) using an in vitro proliferation assay (Fig. 1A). SAG
inhibited lung tumor cell proliferation in all cell lines, with IC50
values ranging from 0.2 to 3.3 nM, and was effective at sub-
nanomolar concentrations (#1 nM) in five of the six cell lines.
Moreover, SAG was consistently more efficacious than PAC.
Sagopilone interferes with cytoskeletal functions and
induces apoptosis in A549 cells
Further experiments on the general mode of action of SAG
were performed with the A549 as model cell line. Vehicle-treated
A549 cells showed a normal microtubule spread in interphase cells
and typical bipolar spindles with congressed chromosomes at the
metaphase plate in mitotic cells (Fig. 1B). In contrast, when A549
cells were incubated with 40 nM SAG marked microtubule
bundling in interphase cells was visible which led to an abnormal
spindle organization in metaphase cells, with multiple spindle
poles, several plates of congressed chromosomes, and an irregular
chromosomal alignment. These cellular effects were dose-depen-
dent and also seen after incubation with 2.5 nM SAG, but to a
lesser extent.
Effects of SAG and PAC on cell cycle progression were
measured in A549 cells in vitro with FACS analysis (Fig. 1C and
Supplementary Fig. S1). Two different phenotypes were observed:
Low concentrations of SAG or PAC (0.5–5 nM and 2–7 nM,
respectively) induced aberrant cell division resulting in the
formation of an increased percentage of aneuploid cells with a
DNA content ,2N or .2N, but only a slight increase in the
percentage of cells in G2/M phase. A different phenotype was
observed at higher concentrations of SAG and PAC (.10 nM):
Here, a dramatic increase in the percentage of cells in the G2/M
phase was observed (Fig. 1C and Supplementary Fig. S1). For
all further analyses of the two different phenotypes, two
concentrations were employed which induce either the aneuploid
Molecular Mode of Action of Sagopilone in NSCLC
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phenotype, i.e. 40 nM SAG or PAC.
A concentration-dependent induction of apoptosis by SAG was
observed in FACS analysis after 72 hrs of incubation. Interesting-
ly, treatment with low concentrations of SAG (2.5, 5, and 10 nM)
effectively inhibited cell proliferation but induced only little
apoptosis, whereas the high concentration SAG treatments
(40 nM and 100 nM) led to pronounced induction of apoptosis
in A549 cells (Fig. 1D).
Strong effects of high concentration, but not by low
concentration sagopilone-treatment on changes in
genome-wide gene expression in A549 cells
RNA was isolated from A549 cells, untreated, vehicle control-
treated, as well as treated with two concentrations each of SAG
(2.5 nM and 40 nM) and PAC (4 nM and 40 nM) for 18 hrs, and
hybridized to Affymetrix HGU133Plus2.0 arrays. High-quality
gene expression data were obtained. A principle component
analysis (PCA) based on the expression of all genes revealed two
main clusters: One cluster contained the untreated, vehicle-treated
and low concentration SAG (2.5 nM)- or PAC-treated (4 nM)
samples, whereas samples treated with high concentrations
(40 nM) of SAG or PAC formed a separate cluster (Fig. 2A, 2B)
indicating that treatment with a low drug concentration of SAG or
PAC induced only relatively small gene expression changes as
compared to the untreated samples, whereas a high drug
concentration of SAG or PAC induced stronger gene expression
changes.
Paired t-tests comparing each treatment group with the vehicle-
treated groups were performed and the results displayed as
Volcano plot (Supplementary Fig. S2) depicting the significance as
a function of the fold change. Four gene lists were generated with
the threshold parameters for P-value and fold change of the high
and low concentration treatments of both compounds were as
described in Table 1, together with the total number and the
number of up- and down-regulated genes. The gene lists obtained
from the statistical tests were compared using Venn diagrams.
From the total of 503 genes regulated by 40 nM PAC and 593 by
40 nM SAG, 391 genes were both regulated by both treatments,
indicating a similar set of genes affected by a high concentration of
both TBAs. A Gene Ontology (GO) analysis of the 391 regulated
genes with the GeneGo Metacore software revealed a similar
occurrence and rank order of biological processes (data not shown)
indicating a very similar mechanism of action for both TBAs at
high concentration. In contrast, when comparing the 593 genes
regulated by 40 nM SAG with the 221 genes affected by treatment
with 2.5 nM of the same drug, only 41 genes were commonly
regulated by both drug concentrations and a meager nine genes
were commonly regulated by 40 nM (total of 503 genes) or 4 nM
PAC (total of 158 genes), which indicated that treatment with a
high versus a low concentration of either SAG or PAC for 18 hrs
regulates a non-overlapping set of genes. When comparing the
effects of 2.5 nM SAG (total of 221 genes) with 4 nM PAC (total of
Figure 2. Differential gene expression induced by high versus low concentration of sagopilone. 2A and 2B. Principle Component
Analysis (PCA) of microarray data of A549 cells untreated (grey), vehicle-treated (dark grey), or treated with 2.5 nM (blue) or 40 nM SAG (dark blue)
and 4 nM (green) or 40 nM PAC (dark green) for 18 hrs. Each plotted sphere represents the expression profile of an individual sample with n=5
independent biological replicates on the projection of the data on the first three principal components, accounting for most of the variability in the
data (labeled axes). Views from two different angles (Fig. 2A, 2B) are shown to visualize the clustering.
doi:10.1371/journal.pone.0019273.g002
Figure 1. Effect of sagopilone (SAG) on cell proliferation, tubulin cytoskeleton, cell cycle and apoptosis of lung cancer cells. 1A, SAG
and PAC inhibit proliferation of lung cancer cell lines. Six different lung cancer cell lines were treated with SAG or PAC for 72 hrs. Proliferation was
measured with crystal violet assay. Mean IC50 values as measure of the half-maximal growth inhibition and standard deviations are shown. 1B,
Immunofluorescence staining of a-tubulin (green) and DNA (red) in A549 lung cancer cells after incubation with either vehicle (0.1% ethanol), 2.5 nM,
or 40 nM SAG. Scale bar =20 mm. Representative pictures of interphase and mitotic cells are shown. 1C, FACS analysis of A549 cells treated with
vehicle, 2.5 and 40 nM SAG or 4 nM and 40 nM PAC for 18 hrs revealed G2/M arrest at 40 nM SAG or PAC and increased numbers of cells with ,2N
and .2N DNA content and enrichment in G0/G1 phase of the cell cycle at 2.5 nM SAG or 4 nM PAC. 1D, Induction of apoptosis by increasing
concentrations of SAG in A549 cells. A549 cells were incubated for 72 hrs with vehicle, or 2.5 nM, 5 nM, 10 nM, 40 nM, or 100 nM SAG. Further, the
cells were stained with 3,39-dihexyloxacarbocyanine iodide (DiOC6(3)) and propidium iodide for FACS measurement. White bars indicate the mean
percentage of cells characterized by decrease of DYm( DYm low) and black bars indicate cells with DYm low and high propidium iodide signal (PI+
and DYm low) due to plasma membrane rupture. The mean of three independent experiments and standard deviation is given.
doi:10.1371/journal.pone.0019273.g001
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about one-fifth of all low concentration PAC and one-seventh of
all low concentration SAG regulated genes. This suggests an
overlapping but also differential effect on gene regulation at low
concentration of SAG or PAC. Among the 30 genes commonly
regulated by SAG and PAC were the TP53 response genes.
Genes involved in G2/M phase transition are upregulated
by high concentration sagopilone treatment
Differentially regulated genes were subjected to pathway
analysis using the GeneGo MetaCore software and database.
Genes involved in G2/M phase transition and mitosis, such as
Cyclin A, Cyclin B, Nek2A and Securin [23]; [24] and genes such
as BUB1, BUBR1 and CDC20, which are components of the
spindle assembly checkpoint (SAC) [25], were upregulated after
treatment with high concentration of SAG or PAC (Table 2).
CDK1, which is essential for the G1/S and G2/M phase
transitions of eukaryotic cells, is down-regulated by 40 nM SAG
or PAC.
As treatment with 40 nM SAG or PAC led to mitotic arrest in
A549 cells we were interested in analyzing the protein expression
levels of the differentially expressed genes involved in G2/M phase
of the cell cycle in dependence of the drug concentration. Both,
SAG and PAC, at 40 nM markedly upregulated protein
expression of Cyclin B1 and BUBR1 (Fig. 3A and 3B) as well as
mRNA expression (Supplementary Fig. S4), whereas treatments at
concentration below 10 nM SAG or 20 nM PAC did not
significantly alter the expression levels of the proteins (Fig. 3A
and 3B) and mRNAs (Supplementary Fig S4). The results revealed
that high concentrations of A549 cells with SAG or PAC -
concurrent with the observed G2/M arrest - led to an
upregulation of genes and proteins involved in the G2/M phase.
Genes involved in DNA damage response are
upregulated by high concentration sagopilone treatment
Interestingly, GO analysis revealed that genes involved in DNA
damage response and repair pathways such as the human DNA
Polymerase epsilon (POLE) [26], XRCC6 and XRCC5 [27], were
found to be upregulated after treatment of A549 cells with 40 nM
SAG or PAC (Table 3). In order to analyze a potential direct effect
of SAG on DNA damage, phoshorylation of histone H2AX was
measured as marker for DNA double strand breaks (DSBs). In
A549 cells, high concentrations of SAG, i.e. at 40 nM and
100 nM, increased phosphorylations of H2AX (Supplementary
Fig. S3A). Treatment with the pan-caspase inhibitor zVAD-fmk
inhibits both phosphorylation of H2AX and PARP cleavage
demonstrating that the SAG-induced increase in DSBs is not a
direct effect of SAG, but rather a consequence of the increased
DSBs which accompanies the apoptosis.
TP53 and direct transcriptional targets of TP53 are
upregulated by low concentration sagopilone treatment
Numerous genes that are direct transcriptional targets of TP53
[28], such as CDKN1A, or GADD45A were upregulated after
treatment of A549 cells with low concentration of SAG or PAC on
the mRNA level (Table 4). Remarkably, A549 cells treated with
2.5 nM SAG showed a more pronounced upregulation of TP53
target genes compared to cells treated with 4 nM PAC (Table 4).
In order to analyze the effects of SAG and PAC on TP53 target
genes in a concentration-dependent manner, A549 cells were
treated with increasing concentration of SAG or PAC which
revealed a bell-shaped curve of gene induction for the TP53 target
genes CDKN1A, MDM2, GADD45A, and FAS: Expression was
induced between 1–10 nM SAG or PAC, whereas concentrations
exceeding 10 nM SAG or PAC resulted in a lower induction of
gene expression (Fig. 3C). Treatment with PAC was consistently
less potent in induction of these four genes.
In order to analyze if the changes observed on the RNA level
were also mirrored by changes on the protein level, immunoblot
analysis of TP53 and CDKN1A were performed from lysates of
A549 cells treated with increasing concentrations of SAG or PAC
for 18 hrs. TP53 and CDKN1A showed increased protein
expression levels after treatment with 0.5–10 nM SAG or PAC
(Fig. 3D and 3E).
Knockdown of TP53 increases apoptosis induction by
low concentration of sagopilone in A549 cells
To further elucidate the role of TP53 activation in response to
SAG, A549 cells containing wild-type TP53 were stably
transfected with expression plasmids containing short hairpin
RNAs (shRNAs) targeting the mRNA of TP53 for knockdown.
The TP53 protein expression level (Fig. 4A) and the TP53 mRNA
(Fig. 4B) were dramatically reduced (80–90%) in the three
independently generated shTP53 A549 cell lines (Fig. 4A, 4B).
Moreover, the transcriptional induction of CDKN1A by SAG was
markedly diminished in the TP53 shRNA knock-down cell lines
when compared with the two control A549 cell lines shCtrl1 and
shCtrl2, in which where p21 was found to be elevated in the
expected manner (Fig. 4C).
The effect of increasing concentrations of SAG on the TP53
knockdown compared to the control shRNA cell lines on apoptosis
induction was measured by FACS. The TP53 shRNA knockdown
cell lines exhibited a significant increase of apoptotic cell numbers
compared to the control A549 when treated with 2.5 nM, 5 nM,
or 10 nM SAG (Fig. 4D). Treatment with SAG at 40 nM and
100 nM led only to marginally elevated induction of apoptosis in
TP53 shRNA knock-down cell lines compared to control cell lines.
The results indicate that activation of TP53 and downstream
effectors by low concentrations of SAG is responsible for the
Table 1. Number of regulated genes after treatment with sagopilone (SAG) or paclitaxel (PAC).
Treatment P-value Fold Change Regulated Genes Up-regulated Down-regulated
4 nM PAC vs. vehicle #5610
23 $3 158 83 75
2.5 nM SAG vs. vehicle #5610
23 $3 221 110 111
40 nM PAC vs. vehicle #1610
25 $5 503 403 100
40 nM SAG vs. vehicle #1610
25 $5 593 455 138
Shown is the number of genes that were either up- or down-regulated obtained from Volcano plots (similar to the one shown in Supplementary Figure 2) using specific
parameters for P-value and fold change.
doi:10.1371/journal.pone.0019273.t001
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mechanism of resistance to SAG.
Discussion
Resistance towards chemotherapy is a main obstacle in
successful lung cancer treatment. Hence the development of new
therapeutic regimens should be accompanied by research on
molecular mechanisms of resistance at the earliest time point. This
could help to identify patient population most likely benefit from
treatment and therefore increasing the chance for a more
successful therapeutic response.
In this study, the cellular and molecular mechanisms instigated
by the new epothilone SAG have further been elucidated and
compared with PAC, a standard TBA, used in combination with
carboplatin for the treatment of NSCLC. We analyzed the efficacy
of SAG compared to PAC in five different lung cancer cell lines in
vitro and showed that SAG was consistently more efficient than
PAC. This is in line with previous articles reporting that SAG has
a higher affinity and selectivity towards the target b-tubulin, which
results in a higher intracellular drug concentration of SAG
compared to PAC [29].
In the past, TBAs were generally believed to cause mitotic
arrest, but more detailed studies have identified two different,
Table 2. Differently expressed genes with relevance to G2/M transition or mitosis after treatment with high concentrations of
sagopilone (SAG) or paclitaxel (PAC).
Identifier Gene Name Gene Symbol FoldChange40 nMSAG FoldChange40 nMPAC
232588_at stromal antigen 1 STAG1 12.50 11.37
207331_at centromere protein F, 350/400 ka (mitosin) CENPF 5.59 5.25
232466_at Cullin 4A CUL4A 4.90 4.66
1556339_a_at Ubiquitin-activating enzyme E1C (UBA3 homolog, yeast) UBE1C 4.03 3.89
215623_x_at SMC4 structural maintenance of chromosomes 4-like 1 (yeast) SMC4L1 3.97 3.75
244427_at Kinesin family member 23 KIF23 3.92 3.33
233940_at Echinoderm microtubule associated protein like 4 EML4 3.51 3.20
242362_at Cullin 3 CUL3 2.74 n.c.
228729_at cyclin B1 CCNB1 2.52 2.35
204641_at NIMA (never in mitosis gene a)-related kinase 2 NEK2 2.25 2.09
221258_s_at kinesin family member 18A KIF18A n.c. 2.09
218755_at kinesin family member 20A KIF20A 2.09 1.93
236974_at Cyclin I CCNI 2.01 n.c.
209408_at kinesin family member 2C KIF2C 1.97 1.84
208079_s_at serine/threonine kinase 6 (aurora kinase A) STK6 1.96 1.86
209642_at BUB1 budding uninhibited by benzimidazoles 1 homolog BUB1 1.92 1.69
202870_s_at CDC20 cell division cycle 20 homolog (S. cerevisiae) CDC20 1.91 1.79
203755_at BUB1 budding uninhibited by benzimidazoles 1 homolog beta BUB1B 1.91 1.69
204170_s_at CDC28 protein kinase regulatory subunit 2 CKS2 1.86 1.81
203418_at cyclin A2 CCNA2 1.86 1.84
210052_s_at TPX2, microtubule-associated protein homolog (Xenopus laevis) TPX2 1.75 1.67
218355_at kinesin family member 4A KIF4A 1.71 1.57
202705_at cyclin B2 CCNB2 1.65 1.64
203554_x_at pituitary tumor-transforming 1 (Securin) PTTG1 1.52 1.50
209714_s_at cyclin-dependent kinase inhibitor 3 CDKN3 1.50 n.c.
223394_at SERTA domain containing 1 SERTAD1 n.c. 1.35
203967_at CDC6 cell division cycle 6 homolog (S. cerevisiae) CDC6 0.48 0.49
213523_at cyclin E1 CCNE1 0.46 0.44
210559_s_at cell division cycle 2, G1 to S and G2 to M CDC2 n.c. 0.46
203213_at cell division cycle 2, G1 to S and G2 to M CDC2 0.42 n.c.
202107_s_at MCM2 minichromosome maintenance deficient 2 MCM2 0.45 0.49
201930_at MCM6 minichromosome maintenance deficient 6 MCM6 0.44 0.45
205296_at retinoblastoma-like 1 (p107) RBL1 0.36 0.40
205034_at cyclin E2 CCNE2 0.22 0.24
From the overall 705 differentially regulated genes in response to treatment with 40 nM SAG or PAC (assessed by pair wise comparisons of treatment versus vehicle and
selection according to Volcano plot with .5fold change, P-value,1610-5 after Affymetrix gene expression analysis) the 34 genes involved in G2/M transition and
mitosis (Gene Ontology classification cell cycle, mitosis or cytokinesis) are shown.
Statistical significance level P,0.001. n.c. = no change.
doi:10.1371/journal.pone.0019273.t002
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19273Figure 3. Validation of differential gene regulation by sagopilone and paclitaxel on the RNA and protein level. 3A, 3B, Increase of
Cyclin B1 protein and BUBR1 protein by high concentrations of SAG (Fig. 3A) and PAC (Fig. 3B) A549 cells were incubated with the indicated
concentrations of SAG or PAC for 18 hours. Cell lysates were subjected to immunoblotting and probed with antibodies recognizing Cyclin B1 and
BUBR1, respectively. GAPDH served as loading control. 3C, Regulation of TP53 target genes by SAG and PAC. A549 cells were incubated with the
indicated concentrations of SAG or PAC for 18 hours and subjected to RNA extraction. Expression of CDKN1A, MDM2, GADD45A, and FAS, was
determined by real-time PCR (TaqMan) and normalized to the expression of the endogenous control gene HPRT. The mean of three independent
experiments and standard deviations are shown. The fold change of the vehicle treated A549 cells was set as 1.0 and the SAG treated samples were
normalized to the vehicle treated A549 cells. 3D, 3E, Increase of TP53 and CDKN1A protein levels by concentrations of SAG or PAC between 0.5–
10 nM. A549 cells were incubated with the indicated concentrations of SAG (Fig 3D) or PAC (Fig. 3E) for 18 hours. Cell lysates were subjected to
immunoblotting and probed with antibodies recognizing TP53, CDKN1A and GAPDH, respectively.
doi:10.1371/journal.pone.0019273.g003
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that this is also the mode of action of SAG in lung cancer cells,
where an aneuploid phenotype is induced by 2.5 nM SAG or
4 nM PAC and, in contrast, a mitotic arrest phenotype is induced
by 40 nM SAG or PAC, indicating that SAG has a similar
concentration-dependent mechanism as PAC. However, we
showed that for PAC the induction of aneuploid cells peaked at
higher concentrations compared to SAG, probably reflecting the
pharmacological differences reported earlier [29].
To explore the differences between the two phenotypes caused
by SAG, we have generated genome-wide gene expression profiles
of A549 cells treated with low and high concentrations of SAG or
PAC, which were analyzed statistically, as well as by pathway
analysis tools including Gene Ontology. Treatment of A549 cells
with 40 nM SAG or PAC for 18 hrs strongly induced differential
gene expression and very similar gene expression profiles by both,
SAG and PAC. Due to the fact that the majority of the cells
arrested at the metaphase/anaphase transition after treatment, the
gene expression patterns mainly showed upregulation of compo-
nents of the SAC and genes involved in mitosis, like BUBR1 and
Cyclin B1, all indicative of a mitotic arrest phenotype induced by
40 nM SAG or PAC. These results are in line with previous
Table 3. Differently expressed genes involved in DNA damage response after treatment with high concentrations of sagopilone
(SAG) or paclitaxel (PAC).
Identifier Gene Name Gene Symbol FoldChange40 nMSAG FoldChange40 nMPAC
1560509_at Polymerase (DNA directed), epsilon POLE 5.88 4.24
237133_at Sterile alpha motif and leucine zipper containing kinase AZK ZAK 3.88 4.38
215308_at Thyroid autoantigen 70 kDa (Ku antigen) G22P1 3.37 3.16
232633_at X-ray repair complementing defective repair
in Chinese hamster cells 5
XRCC5 3.02 2.82
207746_at polymerase (DNA directed), theta POLQ 2.66 2.43
204317_at G-2 and S-phase expressed 1 GTSE1 2.18 n.c.
211040_x_at G-2 and S-phase expressed 1 GTSE1 n.c. 1.99
203554_x_at pituitary tumor-transforming 1 PTTG1 1.52 1.50
208808_s_at high-mobility group box 2 HMGB2 1.51 n.c.
204767_s_at flap structure-specific endonuclease 1 FEN1 n.c. 0.59
205698_s_at mitogen-activated protein kinase kinase 6 MAP2K6 0.48 0.52
From the overall 705 differentially regulated genes in response to treatment with 40 nM SAG or PAC (selected by pairwise comparison and Volcano Plot analysis, see
Table 1), genes were further selected using the search phrases ‘‘DNA damage’’, ‘‘double strand breaks’’, ‘‘DNA repair’’ and ‘‘excision repair’’ in their Gene Ontology
classification. Statistical significance level P,0.01. n.c. = no change.
doi:10.1371/journal.pone.0019273.t003
Table 4. Differential expression of TP53 target genes after incubation with low concentrations of sagopilone (SAG) and paclitaxel
(PAC).
Identifier Gene Name Gene Symbol FoldChange2.5 nMSAG FoldChange4 nMPAC
225912_at tumor protein p53 inducible nuclear protein 1 TP53INP1 2.82 1.90
217373_x_at Mdm2, transformed 3T3 cell double minute 2 MDM2 2.47 n.c.
202284_s_at cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 2.30 1.44
215719_x_at Fas (TNF receptor superfamily, member 6) FAS 2.20 1.32
201236_s_at BTG family, member 2 BTG2 2.18 n.c.
207813_s_at ferredoxin reductase FDXR 1.79 1.34
203725_at growth arrest and DNA-damage-inducible, alpha GADD45A 1.64 n.c.
227345_at tumor necrosis factor receptor superfamily, member 10d TNFRSF10D 1.57 n.c.
219628_at p53 target zinc finger protein WIG1 1.51 n.c.
223342_at ribonucleotide reductase M2 B (TP53 inducible) RRM2B 1.47 n.c.
208478_s_at BCL2-associated X protein BAX n.c. 1.29
203409_at damage-specific DNA binding protein 2, 48 kDa DDB2 1.29 1.30
209295_at tumor necrosis factor receptor superfamily, member 10b TNFRSF10B 1.28 n.c.
1563016_at Acetyl-Coenzyme A carboxylase alpha ACACA 0.21 0.70
From the overall 349 differentially regulated genes in response to treatment with 2.5 nM SAG or PAC (selected by pairwise comparison and Volcano Plot analysis, see
Table 1), genes were further selected according to their transcriptional activation by TP53 (Riley et. al., 2008).
Statistical significance level P,0.05, n.c. = no change.
doi:10.1371/journal.pone.0019273.t004
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PAC [31]; [32]. Moreover, a recent report about primary NSCLC
mouse xenograft models treated with SAG unveiled a highly
significant upregulation of genes involved in pathways like SAC
and chromosome segregation in the primary NSCLC xenograft
models which are SAG responders compared to non-responder
[7], indicating that the phenotype observed in vitro after treatment
with the high concentration of SAG is mainly responsible for
tumor cells killing.
Induction of DNA damage response genes and the phosphor-
ylation of histone H2AX, which marks DNA as prerequisite for
repair process to take place, at 40 nM SAG, as reported here,
might be due to direct induction of DNA damage by high
concentration of SAG. As treatment with the pan-caspase
inhibitor zVAD-fmk inhibits both phosphorylation of H2AX and
PARP cleavage indicates that the SAG-induced increase in DSBs
is not direct effect of SAG, but rather the consequence of the
increased apoptosis. However, up to now, the role of DSBs and the
phosphorylation of H2AX in response to SAG and its potential
role in the mechanistic activity of SAG will need further
investigation.
In our studies, treatment of A549 cells with low concentrations
of SAG or PAC resulted in stabilization of TP53 and induction of
TP53 target genes, potentially resulting from consistent translation
of the long-lived TP53 mRNA during prolonged mitosis induced
by both drugs [33]; [34]; [35]. However, it should be noted that
induction of TP53 target genes was more pronounced after SAG
treatment.
This upregulation of TP53 target genes such as CDKN1A or
GADD45A, mostly resembled an activation pattern which is
caused in response to mild, repairable damage, and induced cell
cycle arrest, rather than strong damages which promote apoptosis
[36]; [28]; [37]. This allows repair processes to take place and the
cells to survive. In terms of chemotherapy this would indicate an
unfavorable condition, because the cells might start regrowing
after a terminal cell cycle arrest. The aneuploid cells finally arrest
in the G1 state due to a postmitotic checkpoint that is dependent
on TP53 [38]. TP53 mediates G1 arrest mainly by increasing
protein levels of the cyclin-dependent kinase (CDK) inhibitor p21
(CDKN1A) [39]. Apart from functions in cell cycle regulations
several anti-apoptotic functions of p21 have been described [40];
[41]; [42]; [43]. Moreover, the weak apoptosis induction after low
concentration SAG treatment of A549 cells compared to high
concentrations leads to the conclusion that anti-apoptotic effects of
TP53 overweigh in this phenotype.
To date the role of TP53 in the sensitivity of cancer cells to
TBAs is contested [14]; [15]. Many groups reported that cells
lacking wild type TP53 displayed increased sensitivity to PAC
[16]; [44]; [45]. Sensitization of TP53 wild type (wt) cells to low
concentration PAC was achieved by by siRNA-mediated knock-
down of TP53 in NCI-H460 cells [46]. Furthermore, the gene
transfection of TP53-null human non-small cell lung cancer H358
cells with wt TP53 resulted in loss of PAC sensitivity [47].
To address the question whether TP53 plays a role in the
sensitivity towards SAG, we analyzed the effect of TP53 knock
down on the apoptosis induction of A549 cells. We have shown
that the knockdown of TP53 increased the rate of apoptosis after
low concentration SAG treatment in A549 cells. These effects in
A549 TP53 knockdown cells were mostly based on abrogation of
TP53-mediated transcription at low concentration of SAG. The
TP53-dependent CDKN1A induction was coincident with
resistance to low concentration SAG-induced apoptosis in A549
cells. Thus, the transactivation of TP53 is responsible for the low
apoptosis induction of A549 cells in vitro after treatment with low
concentration SAG. Pharmacological inhibition of TP53 using
pifithrin-a could be a second method to validate the role of TP53
in SAG efficacy. Results from previous studies show that the
sensitizing effects of pifithrin-a towards microtubule inhibiting
drugs [48]; [46] is well in accordance with the findings of our study
for SAG in NSCLC.
On the other hand it has been shown that pifithrin-a is not
completely specific in its action on TP53, as it is known to have
targets other than TP53 [49]; [50]; [51] and pifithrin-a is known
to protect cells from DNA damage-induced apoptosis by a p53-
independent mechanism [52]. Therefore in the current study we
used shRNA based knockdown of TP53 as the most specific
method on otherwise genetically identical cell lines.
It might be possible that in tumors, harboring areas with low
vascularization only very low amounts of SAG will actually reach
the tumor cells. In that case, the aneuploid phenotype (here
Figure 4. Knockdown of TP53 increases apoptosis induction by low concentration sagopilone. 4A; shRNA mediated knockdown of TP53
in A549 cells after lentiviral transduction and hygromycin selection. A549 cell were stably transduced with three different shRNAs targeting the mRNA
of TP53 (shTP53_1, shTP53_2, shTP53_3) or two different control shRNAs (shCtrl1 or shCtrl2). TP53 protein is strongly downregulated in A549 cells
stably transfected with shRNAs targetting TP53. Lysates from A549 cells with shRNA-mediated TP53 knockdown and sh control cells were subjected
to immunoblotting and probed with antibodies recognizing TP53 and GAPDH, respectively. 4B, TP53 mRNA is downregulated in A549 shTP53 cells.
TP53 gene expression in A549 shTP53 knockdown and control cell lines were determined by real-time PCR (TaqMan) and normalized to the
endogenous control (HPRT). The mean TP53 expression of shCtrl1 was set as 1.0 and the TP53 expression of the control shRNA or TP53 shRNA was
normalized to the expression of shCtrl1. Shown is the average of three independent experiments and standard deviations. 4C, TP53 knockdown
inhibits CDN1A induction by SAG. Regulation of TP53 target gene CDKN1A by SAG. A549 shTP53 knockdown and control cell lines cells were
incubated with the indicated concentrations of SAG for 18 hours and subjected to RNA extraction. Expression of CDKN1A was determined by real-
time PCR (TaqMan), normalized to the endogenous control (HPRT). Shown is the average of three independent experiments and standard deviations.
The average expression of the control shRNA shCtrl1 was set as 1.0 and the SAG treated shTP53 knock down cell lines were normalized to the control.
4D. Knockdown of TP53 increases apoptosis induction by low concentration SAG Apoptosis induction by SAG after 72 hours. A549 sh RNA controls
(shCtrl1, shCtrl2) and TP53 shRNA knockdown cell lines (shTP53_1, shTP53_2, shTP53_3) were treated for 72 hrs with vehicle, or 2.5 nM, 5 nM, 10 nM,
40 nM, or 100 nM SAG. Afterwards, the cells were stained with DiOC6(3) and propidium iodide for FACS detection of apoptosis-associated
mitochondrial membrane potential dissipation (DY m low) and in combination with plasma membrane rupture (PI + and DY m low). White bars
indicate the mean percentage of cells characterized by decrease of DYm( DYm low) and black bars indicate cells with DYm low and high propidium
iodine signal (PI+) due to plasma membrane rupture. Three independent experiments were performed. For statistic significance One-way ANOVA
analysis followed by the Bonferroni a posteriori test was performed comparing the response of the control A549 cell line with the shTP53 cell lines
treated with the same SAG concentration or vehicle. The mean apoptosis induction was significantly higher in the three shTP53 cell lines treated with
5 nM SAG than in the control group treated with 5 nM SAG (ANOVA, F=56.68, p,0.0002), shTP53_1 vs control (ANOVA/Bonferroni, t=8.195,
p,0.01), shTP53_2 vs control (ANOVA/Bonferroni, t=11.16, p,0.01), shTP53_3 vs control (ANOVA/Bonferroni, t=7.405, p,0.01). The mean apoptosis
induction was significantly higher in two shTP53 cell lines treated with 10 nM SAG than in the control group treated with 10 nM SAG (ANOVA,
F=18,81, p,0.0032), shTP53_1 vs control (ANOVA/Bonferroni, t=5.171, p,0.05), shTP53_2 vs control (ANOVA/Bonferroni, t=6.992, p,0.05), while
no significant difference was observed between shTP53_3 vs control (ANOVA/Bonferroni, t=4.750, p.0.05).
doi:10.1371/journal.pone.0019273.g004
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subsequently result in a G1 arrest. Under that condition, the TP53
response would play an important role. It is an open question
whether in vivo these cells then die from apoptosis or were arrested
for a certain time and start regrowing eventually, which is well in
accordance with data from a recent study in patient derived
NSCLC xenografts showing a better long-term response to SAG in
models with mutated TP53 [7].
About half of all NSCLC cases harbor mutations in TP53 [13].
The question remains whether these tumors might have a higher
probability to respond to SAG. SAG is currently in clinical
development and has been evaluated in phase II trials in NSCLC
[53]; [54] therefore investigations whether mutational status of
TP53 could serve as predictive biomarker in clinical trials warrants
further investigation. Additionally, it could be of clinical relevance
if patients with TP53 wild type tumors benefit from combination
therapy with drugs inhibiting TP53. Those drugs would enhance
the effect of SAG therapy and concurrently would help to reduce
the systemic chemotherapy-induced toxicity [55]. As the currently
available TP53 inhibitors such as pifithrin-a are not appropriate
for clinical application. TP53 inhibitors that more specifically
inhibit certain functions of TP53 i.e. those that block TP53-
dependent transactivation (with no effect on p53-mediated
apoptosis) are needed.
Supporting Information
Figure S1 Cell cycle analysis of A549 cells treated with
different concentrations sagopilone and paclitaxel. Cells
were incubated with growth medium containing 0 to 100 nM SAG
and PAC for 18 hours, followed by fixation and incubation with
propidium iodide. DNA content was determined by flow cytometry.
The amounts of cells constituting the aneuploid, G1, S and G2/M
populations were determined using ModFit software and plotted
against the drug concentration. S phase cells are not shown because
of clarity. Mean values and standard deviation given.
(TIF)
Figure S2 Volcano plot from T-test of 40 nM sagopilone
vs. vehicle (threshold: .5-fold change, P-value ,1610
25).
The Volcano plot depicts the significance as a function of the fold
change. Thus, highly significant genes with a low fold change as
well as genes which possess a high fold change and a relatively low
significance were indicated in red. Thresholds for the Volcano
plots were defined as ellipse with .5-fold change and P-value
,1610
25 from T-test for 40 nM SAG and PAC and for 2.5 nM
SAG and 4 nM PAC as ellipse with .3-fold change and P-value
,5610
23.
(TIF)
Figure S3 cH2AX as marker for DNA double strand
breaks and apoptosis. (A) A549 cell were treated with
increasing concentrations of SAG for 18 hours and subjected to
western blot analysis. cH2AX antibody staining is shown. (B)
Western blot analysis of A549 cells treated with 40 nM SAG for
different times in the presence (+zVAD) (40 mM) or absence
(-zVAD) of ZVAD.fmk and probed with antibodies detecting
PARP, cH2AX, MPM2, respectively. GAPDH served as loading
control.
(TIF)
Figure S4 Regulation of gene expression of Cyclin B1,
BUBR1 and TP53 by sagopilone and paclitaxel. A549 cells
were incubated continuously with medium containing increasing
concentrations of both agents for 18 hours and were subjected to
RNA extraction. After performing a reverse transcription the
cDNA was subjected to real time PCR (TaqMan) of Cyclin B1,
BUBR1 and TP53. Shown is the fold change compared to the
vehicle treated samples as mean of three independent experiments
and standard deviations.
(TIF)
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